Mislocalization of p27 to the cytoplasm of breast cancer cells confers resistance to anti-HER2 targeted therapy
Metrics: PDF 1350 views | HTML 1723 views | ?
Hui Zhao1,*, Claire M. Faltermeier1,*, Lori Mendelsohn2, Peggy L. Porter3,4, Bruce E. Clurman5, James M. Roberts1
1Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
2Biology Department, Whitman College, Walla Walla, Washington, USA
3Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
4Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
5Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
*These authors contributed equally to this work
James M. Roberts; e-mail: email@example.com
Keywords: p27Kip1 (p27), cell proliferation, cytoplasmic localization, Her2+ breast cancer cells, lapatinib, drug sensitivity
Received: December 05, 2014 Accepted: December 08, 2014 Published: January 03, 2015
As a cell cycle inhibitor and tumor suppressor, p27 is frequently misregulated in human cancers. Increased degradation is the most common mechanism of misregulation, however in some cancers, p27 is mislocalized from its cell cycle inhibitory location in the nucleus, to the cytoplasm. In normal cells cytoplasmic p27 has functions that are distinct from its cell cycle-regulatory nuclear functions. Therefore, an important question is whether localization of p27 to the cytoplasm in tumor cells is primarily a mechanism for cancelling its inhibitory effect on cell proliferation, or whether cytoplasmic p27 has more direct oncogenic actions. To study p27 mislocalization in human cancers we screened a panel of common breast cancer cell lines. We observed that p27 accumulated in the cytoplasm exclusively in cell lines that are Her2+. To address the significance of p27 mislocalization in Her2+ breast cancer cells we interrogated the cellular response to the dual-Her2/EGFR kinase inhibitor, lapatinib. Knockdown of p27 using shRNA sensitized Her2+ cells to lapatinib-induced apoptosis. Moreover, expression of a constitutively cytoplasmic form of p27 (p27ΔNLS) reversed the lapatinib-induced apoptosis, suggesting that cytoplasmic p27 contributed to lapatinib resistance in Her2+ breast cancer cells by suppressing apoptosis. Our results suggest that p27 localization may be useful as a predictive biomarker of therapeutic response in patients with Her2+ breast cancers.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.